CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NYSEMKT
- Symbol: CRMD
Companies Related to CorMedix:
- Previous Close: $2.24
- 50 Day Moving Average: $1.90
- 200 Day Moving Average: $1.99
- 52-Week Range: $1.35 - $4.54
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.86
- P/E Growth: 0.00
- Market Cap: $87.04M
- Outstanding Shares: 40,296,000
- Beta: 0.24
What is CorMedix's stock symbol?
CorMedix trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "CRMD."
Where is CorMedix's stock going? Where will CorMedix's stock price be in 2017?
2 brokers have issued 1-year price targets for CorMedix's shares. Their predictions range from $4.00 to $7.50. On average, they expect CorMedix's share price to reach $5.75 in the next year.
When will CorMedix announce their earnings?
CorMedix is scheduled to release their next quarterly earnings announcement on Tuesday, March, 14th 2017.
Who owns CorMedix stock?
CorMedix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Private Advisor Group LLC (0.24%) and Franklin Resources Inc. (0.19%). Company insiders that own CorMedix stock include Antony Pfaffle, Cora M Tellez, Janet Dillione, Khoso Baluch, Matthew Duffy, Randy Milby, Steven W Lefkowitz and Taunia Markvicka.
Who sold CorMedix stock? Who is selling CorMedix stock?
CorMedix's stock was sold by a variety of institutional investors in the last quarter, including Private Advisor Group LLC. Company insiders that have sold CorMedix stock in the last year include Antony Pfaffle, Matthew Duffy and Steven W Lefkowitz.
Who bought CorMedix stock? Who is buying CorMedix stock?
CorMedix's stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc.. Company insiders that have bought CorMedix stock in the last two years include Cora M Tellez, Janet Dillione, Khoso Baluch, Randy Milby and Taunia Markvicka.
How do I buy CorMedix stock?
Shares of CorMedix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CorMedix stock cost?
One share of CorMedix stock can currently be purchased for approximately $2.16.